Drugs / REP 2165
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02565719 | Mar 2016 → May 2019 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REP 2165 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02565719 ↗ |
| Known as | REP 2165-Mg | “REP 2165-Mg = magnesium chelate complex of REP 2165” NCT02565719 ↗ |